The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease
Open accessAbstract
Growing evidence demonstrates that circulating tumor DNA (ctDNA) minimal residual disease (MRD) following treatment for solid tumors predicts relapse. These results suggest that ctDNA MRD could identify candidates for adjuvant therapy and measure response to such treatment. Importantly, factors such as assay type, amount of ctDNA release, and technical and biological background can affect ctDNA MRD results. Furthermore, the clinical utility of ctDNA MRD for treatment personalization remains to be fully established. Here, we review the evidence supporting the value of ctDNA MRD in solid cancers and highlight key considerations in the application of this potentially transformative biomarker.Significance: ctDNA analysis enables detection of MRD and predicts relapse after definitive treatment for solid cancers, thereby promising to revolutionize personalization of adjuvant and consolidation therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is a growing body of data demonstrating numerous clinical applications for ctDNA in adults with solid tumors, ranging from prognostication and evaluation of minimal residual disease (MRD) to detection of targetable alterations.7–12”
From Clinical Liquid Biopsy Testing for Detection of Actionable Genomic Alterations in Children and Young Adults With Advanced Solid Tumors on the GAIN Study (2026) · cites this paper as [7]
In the citing paper
“although its clinical utility for directing treatment escalation or de-escalation remains under prospective evaluation [ 9 , 10 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Across early-stage solid tumors, postoperative or post-treatment ctDNA detection is consistently associated with a higher risk of recurrence”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“ctDNA analysis has developed most rapidly in common epithelial malignancies, where it is now used for selected advanced-cancer genotyping scenarios and is being actively evaluated for MRD and molecular relapse monitoring after curative-intent therapy [ 5 , 9 , 10 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“In early-stage solid tumors, ctDNA detection after curative-intent therapy has shown strong clinical validity for predicting future relapse”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Among liquid-biopsy analytes, ctDNA is currently the most clinically mature for sarcoma monitoring because it can capture tumor-specific genomic and epigenomic alterations through a minimally invasive and repeatable blood test [ 5 , 9 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“MRD detection requires greater analytical sensitivity than baseline genotyping or advanced-disease resistance monitoring, because tumor-derived DNA may represent only a very small fraction of total cell-free DNA after definitive therapy [ 5 , 9 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Tumor-informed assays can improve sensitivity by tracking patient-specific alterations identified from tissue sequencing”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“whereas tumor-naïve approaches may be useful when tissue is unavailable or when methylation, fragmentomic, or copy-number signals provide sufficient discriminatory power [ 9 , 10 , 11 , 12 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“MRD detection is the most clinically ambitious use of ctDNA in sarcoma. It requires substantially greater analytical sensitivity than baseline genotyping because tumor-derived DNA may be present at very low levels after surgery or definitive therapy [ 5 , 9 , 10 , 11 , 12 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
In the citing paper
“Tumor-informed assays can track multiple patient-specific alterations at high depth, improving sensitivity for low-level residual disease [ 9 , 16 ].”
From Signals Alongside Scans: A Genomics-Guided Framework for Liquid Biopsy in Bone and Soft-Tissue Sarcomas (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21654 · Cited by 16,522
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Next-generation DNA sequencing
Shendure, J., & Ji, H. (2008) · Nature Biotechnology · doi:10.1038/nbt1486 · Cited by 4,509
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. �., & Pantel, K. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3066 · Cited by 2,897
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
Conroy, T., Hammel, P., Hebbar, M., Ben Abdelghani, M., Wei, A. C., Raoul, J.-L., Choné, L., Francois, E., Artru, P., Biagi, J. J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809775 · Cited by 2,874
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Pignon, J.-P., Tribodet, H., Scagliotti, G. V., Douillard, J.-Y., Shepherd, F. A., Stephens, R. J., Dunant, A., Torri, V., Rosell, R., Seymour, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9030 · Cited by 2,642
Research works printed but not linked: 1
- Pierson-Perry, 2012, Evaluation of detection capability for clinical laboratory measurement procedures: approved guideline
Cited by
Sorted by citations
Items 101–200 of 327
Advances in early detection methods for solid tumors
Jiang, B., Xie, D., Wang, S., Li, X., & Wu, G. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1091223 · Cited by 17
Recent Advances in Perioperative Immunotherapies in Lung Cancer
Fukuda, S., Suda, K., Hamada, A., & Tsutani, Y. (2023) · Biomolecules · doi:10.3390/biom13091377 · Cited by 18
McGale, J., Howell, H. J., Beddok, A., Tordjman, M., Sun, R., Chen, D. L., Wu, A. M., Assi, T., Ammari, S., & Dercle, L. (2024) · Pharmaceuticals · doi:10.3390/ph17020210 · Cited by 16
Liu, Z., Wang, G., Yang, Y., Su, Y., Zhang, H., Liu, J., Cui, P., Fan, X., Yang, J., Zhang, Z., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102334 · Cited by 18
Klocker, E. V., Hasenleithner, S. O., Bartsch, R., Gampenrieder, S. P., Egle, D., Singer, C. F., Rinnerthaler, G., Hubalek, M., Schmitz, K., Bagó-Horváth, Z., et al. (2024) · Molecular Oncology · doi:10.1002/1878-0261.13671 · Cited by 19
ctDNA and Recurrence Risk for Adjuvant De-Escalation in HPV-Positive Oropharyngeal Carcinoma
Routman, D. M., Abel, K. M. V., Price, K. A. R., Moore, E. J., Patel, S. H., Hinni, M. L., Fruth, B. F., Foster, N. R., Yin, L. X., Neben-Wittich, M. A., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2025.0903 · Cited by 15
Valenza, C., Trapani, D., & Curigliano, G. (2022) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000905 · Cited by 15
Overview of the role of liquid biopsy in cancer management
Assi, T., Khoury, R., Ibrahim, R., Baz, M., Ibrahim, T., & Cesne, A. L. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101702 · Cited by 15
Serafini, M. S., Molteni, E., Nicolò, E., Gerratana, L., Reduzzi, C., & Cristofanilli, M. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100132 · Cited by 14
Perioperative Immunotherapy — A KEY toward Improved Outcomes for Early-Stage Lung Cancer?
Lovly, C. M. (2023) · New England Journal of Medicine · doi:10.1056/nejme2305762 · Cited by 13
Co-Occurring Genomic Alterations in NSCLC: Making Order into a Crowded List
Attili, I., Fabrizio, F. P., & de Marinis, F. (2025) · Cancers · doi:10.3390/cancers17142388 · Cited by 13
Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma
SIMONI, E. D., Spagnolo, F., Gandini, S., Gaeta, A., Rizzetto, G., Molinelli, E., Simonetti, O., Offidani, A., & Queirolo, P. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102788 · Cited by 15
Modulating cell-free DNA biology as the next frontier in liquid biopsies
Tabrizi, S., Martin-Alonso, C., Xiong, K., Bhatia, S. N., Adalsteinsson, V. A., & Love, J. C. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.11.007 · Cited by 13
Impact of Higher Cell-Free DNA Yields on Liquid Biopsy Testing in Glioblastoma Patients
Iorgulescu, J. B., Blewett, T., Xiong, K., Crnjac, A., Liu, R., Sridhar, S., Braun, D. A., Sellars, M., Cheng, J., Rhoades, J., et al. (2025) · Clinical Chemistry · doi:10.1093/clinchem/hvae178 · Cited by 16
Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis
Mittal, A., Moltó, C., Tamimi, F., Iorio, M. R. D., Al-Showbaki, L., Cescon, D. W., & Amir, E. (2023) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkad040 · Cited by 13
Provencio, M., Serna-Blasco, R., Nadal, E., González-Larriba, J. L., Martínez‐Martí, A., Bernabé, R., Bosch‐Barrera, J., Calvo, V., Molla, A. I., Reguart, N., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-2958 · Cited by 16
Guo, N., Zhou, Q., Chen, X., Zeng, B., Wu, S., Zeng, H., & Sun, F. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.01.003 · Cited by 12
Liu, Y., Liu, S., Zhen, D.-S., Huang, J., & He, F.-J. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c00484 · Cited by 10
Clinical utility of plasma cell-free DNA in gliomas
Carpenter, E. L., & Bagley, S. J. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac014 · Cited by 12
O’Sullivan, H., Feber, A., & Popat, S. (2023) · OncoTargets and Therapy · doi:10.2147/ott.s322242 · Cited by 11
Rolfo, C. D., Russo, A., & Malapelle, U. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104605 · Cited by 12
Martens, G. A., Demol, J., Dedeurwaerdere, F., Breyne, J., Smet, K. D., Jaeger, P. D., & Smet, D. D. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102235 · Cited by 12
Zhang, J., Liu, S., Gao, X., Liu, S. M., Yan, B., Huang, C., Jiao, Z., Yan, H., Pan, Y., Dong, S. X., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2909 · Cited by 13
Clinical applications of cell-free DNA-based liquid biopsy analysis
Yazaki, S., Tokura, M., Aiba, H., Kojima, Y., & Shiraishi, K. (2025) · Translational Oncology · doi:10.1016/j.tranon.2025.102519 · Cited by 13
Novel Methods to Assess Tumor Burden and Minimal Residual Disease in Genitourinary Cancers
Barata, P. C., Zarrabi, K. K., Bex, A., Grivas, P. D., Hermann, K., Hofman, M. S., Li, R., Antonio Lopez-beltran, B., Padani, A. R., Powles, T. B., et al. (2024) · European Urology · doi:10.1016/j.eururo.2024.11.011 · Cited by 11
Bharde, A., Nadagouda, S., Dongare, M., Hariramani, K., Basavalingegowda, M., Haldar, S., D’Souza, A., Jadhav, B., Prajapati, S., Jadhav, V. L. B., et al. (2024) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2024.100284 · Cited by 11
Radigan, R., Kao, C. S., Krainock, M. R., Liu, M. C., Gupta, V., Alexander, L., Missios, S., Hsu, J., Sangal, A., Milano, M. T., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-88266-z · Cited by 11
Longitudinal ctDNA profiling in precision oncology and immunο-oncology
Filis, P., Kyrochristos, I. D., Korakaki, E., Baltagiannis, E. G., Thanos, D., & Roukos, D. H. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103540 · Cited by 12
Minimal residual disease in solid tumors: an overview
Ma, Y., Gan, J., Bai, Y., Cao, D., & Jiao, Y. (2023) · Frontiers of Medicine · doi:10.1007/s11684-023-1018-6 · Cited by 13
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma
Augustin, R. C., & Luke, J. J. (2024) · American Journal of Clinical Dermatology · doi:10.1007/s40257-024-00852-5 · Cited by 10
Zollinger, D. R., Rivers, E., Fine, A. D., Huang, Y., Son, J., Kalyan, A., Gray, W., Baharian, G., Hammond, C., Ram, R. R., et al. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302129 · Cited by 10
Lv, D., Lan, B., Guo, Q., Yi, Z., Qian, H., Guan, Y., Peng, X., Chen, T., & Ma, F. (2025) · BMC Medicine · doi:10.1186/s12916-025-03959-6 · Cited by 11
Helou, V., Smith, J. D., Harris, M. K., Earland, N. J., Contrera, K. J., Chaudhuri, A. A., & Zevallos, J. P. (2025) · Head & Neck · doi:10.1002/hed.28138 · Cited by 10
Khan, A. U., Jasim, Y. H., Shahid, K., Baxtiyorovich, S. J., Atamuratova, Z., & Urazbaeva, D. (2025) · Clinical & Translational Oncology · doi:10.1007/s12094-025-04073-y · Cited by 11
Liquid Biopsies for Molecular Biology-Based Radiotherapy
Blomain, E. S., & Moding, E. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011267 · Cited by 10
Self-citationYahya, J. B., Baber, M., Nabavizadeh, N., Goodyear, S. M., & Kardosh, A. (2023) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-022-00906-z · Cited by 11
Whiteside, T. L. (2023) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2023.2178902 · Cited by 9
Circulating cell-free (cf)DNA analysis: Current technologies and applications in gynecologic cancer
Kim, S. H., & Weigelt, B. (2024) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2024.101431 · Cited by 9
Sample Collection and Processing in Volatile Organic Compound Analysis for Gastrointestinal Cancers
Zheng, W., Min, Y., Pang, K., & Wu, D. (2024) · Diagnostics · doi:10.3390/diagnostics14141563 · Cited by 9
Chen, P., Zhang, X., Zhan, X., Huang, Y., Wu, H., Zhao, C., Xu, A., & Guan, B. (2025) · Nano Letters · doi:10.1021/acs.nanolett.4c06490 · Cited by 9
Circulating tumor DNA in colorectal cancer: biology, methods and applications
Chen, H., An, Y., Wang, C., & Zhou, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02220-z · Cited by 10
Revolution of Circulating Tumor DNA: From Bench Innovations to Bedside Implementations
Yan, X., Su, J., & Wang, Z. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060428 · Cited by 12
Mohiuddin, M. (2025) · Health Science Reports · doi:10.1002/hsr2.71409 · Cited by 12
Yang, F., Xu, C., Li, C., Xiang, X., Zhao, Y., Hu, C., Rong, H., He, Y., Li, J., Wang, Y., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf1383 · Cited by 9
Tan, A. C., Liao, B.-C., Li, M., Lee, D. J., Uehara, Y., Thamlikitkul, L., Zhang, J.-T., Zheng, M., Lee, C. K., Pavlakis, N., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103696 · Cited by 11
Liu, Z., Han, Y., Dang, Q., Xu, H., Zhang, Y., Duo, M., Lv, J., Li, H., Kong, Y., & Han, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109173 · Cited by 9
Khan, S. R., Scheffler, M., Soomar, S. M., Rashid, Y. A., Moosajee, M., Ahmad, A., Raza, A., & Shahab Uddin, M. S. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154455 · Cited by 9
Advances in application of circulating tumor DNA in ovarian cancer
Xia, T., Fang, C., & Chen, Y. (2023) · Functional & Integrative Genomics · doi:10.1007/s10142-023-01181-2 · Cited by 9
Build the virtual cell with artificial intelligence: a perspective for cancer research
Yang, T., Wang, Y., Ma, F., Xu, B., & Qian, H. (2025) · Military Medical Research · doi:10.1186/s40779-025-00591-6 · Cited by 9
Circulating tumor DNA (ctDNA) application in investigation of cancer: Bench to bedside
Alsaab, H. O., Alzahrani, M. S., Bahauddin, A. A., & Almutairy, B. S. (2024) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2024.110066 · Cited by 9
Zhou, Q., Chen, X., Zeng, B., Zhang, M., Guo, N., Wu, S., Zeng, H., & Sun, F. (2024) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2024.05.007 · Cited by 10
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementation
Lin, X., Liu, B., Wu, J., Shi, L., Zhang, Y., Yang, Q., Tang, H., Xu, S., Gao, Y., Cui, J., et al. (2026) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2026.103108 · Cited by 8
Oliveira, B. B., Costa, B. G. L. D. M., Morão, B., Faias, S. R., Veigas, B., Pereira, L. P., Albuquerque, C. M., Maio, R., Cravo, M. L., Fernandes, A. R., et al. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04696-6 · Cited by 8
Evaluation of Molecular Residual Disease by a Fixed Panel in Resectable Colorectal Cancer
Yang, J., Yu, C., Li, H., Peng, D., Zhou, Q., Yao, J., Lv, J., Fang, S., Shi, J., Wei, Y., et al. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2023.1371 · Cited by 8
Zhang, C., Zhang, C., Wang, K., & Wang, H. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04338-6 · Cited by 8
Luo, X., Zhang, L., Li, Y., Li, C., Sun, G., Zhang, C., Fu, Y., Lv, H., Liu, M., Cui, H., et al. (2024) · Clinical Chemistry · doi:10.1093/clinchem/hvae138 · Cited by 7
Fang, C.-Y., Wen, J., Wu, J., Li, Z., Huang, S., Huang, Y., Chen, J., Su, H., Xie, X., Luo, K., et al. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00310-6 · Cited by 7
Biomarkers for Early Detection and Monitoring of Colorectal Cancer
Char, S. K., Singh, H., & Ng, K. (2025) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2025.10.002 · Cited by 7
Nielsen, L. R., Stensgaard, S., Meldgaard, P., & Sørensen, B. S. (2024) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2024.100802 · Cited by 7
Monitoring advanced gastrointestinal stromal tumor with circulating tumor DNA
Gómez-Peregrina, D., Cicala, C. M., & Serrano, C. (2024) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001040 · Cited by 7
Mirandola, A., Kudriavtsev, A., Muñoz, C. I. C., Comas, R., Macagno, M., Daoud, S., Sánchez, C., Pastor, B., Pisareva, E., Marin, M. S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105352 · Cited by 8
Blomain, E. S., Soudi, S., Wang, Z., Somani, A., Subramanian, A., Nouth, S. C. L., Oladipo, E. D., New, C., Kenney, D. E., Nemat‐Gorgani, N., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-3281 · Cited by 8
Self-citationHow to detect cancer early using cell-free DNA
Hasenleithner, S. O., & Speicher, M. R. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.11.009 · Cited by 7
Genomic profiling and metastatic risk in early-stage non–small cell lung cancer
Fick, C. N., Dunne, E. G., Lankadasari, M. B., Mastrogiacomo, B., Asao, T., Vanstraelen, S., Liu, Y., Sánchez-Vega, F., & Jones, D. R. (2023) · JTCVS Open · doi:10.1016/j.xjon.2023.10.016 · Cited by 7
Yang, W., Ma, S., Fang, Z., Liu, Y., Zhang, X., Wang, F., Wang, C., Wang, Y., Wang, X., Chen, W., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002341 · Cited by 6
Liu, R., Yang, Y., Hu, Z., & Fu, Y. (2026) · World Journal of Surgical Oncology · doi:10.1186/s12957-026-04238-1 · Cited by 7
Eslinger, C. R., Wu, C. S.-Y., & Ahn, D. H. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-24-81 · Cited by 7
Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment
Zhou, J., Mo, H., Hu, D., Zhao, X., Zhou, H. K., & Pan, J. (2023) · Cancer Medicine · doi:10.1002/cam4.6544 · Cited by 6
Ewongwo, A. N., Hui, C., & Moding, E. J. (2024) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2023.12.002 · Cited by 6
Self-citationWhen can we be confident of surgical cure with ctDNA?
Frankell, A. M., & Jamal‐Hanjani, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00664-8 · Cited by 6
Aredo, J. V., Wakelee, H. A., Hui, A. B., Padda, S. K., Joshi, N. D., Guo, H. H., Chaudhuri, A. A., Diehn, M., Loo, B. W., & Neal, J. W. (2022) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2022.100659 · Cited by 6
Self-citationLiquid biopsy in breast cancer management: From circulating biomarkers to clinical breakthroughs
Taki, . G., Shareef, A., Baldaniya, L., Oweis, R. J., Jyothi, S. R., Singh, U., Sahoo, S., Chauhan, A. S., Khazratov, A., Sameer, H. N., et al. (2025) · Journal of Investigative Medicine · doi:10.1177/10815589251366905 · Cited by 5
Dynamic Monitoring of Recurrent Ovarian Cancer Using Serial ctDNA: A Real-World Case Series
Rios‐Doria, E., Reichel, J. B., Radke, M. R., Manhardt, E., Rubin-Saika, M., Lockwood, C. M., Swisher, E. M., & Banda, K. (2025) · Current Oncology · doi:10.3390/curroncol32100585 · Cited by 5
Patil, V., Sharma, A., Parekh, B. K., Jyothi.S, R., Priyadarshini‐Nayak, P., Janney-J, B., Singh, G., Al-Hasnaawei, S., & Kumar-Mishra, M. (2026) · Molecular Neurobiology · doi:10.1007/s12035-025-05634-6 · Cited by 5
Circulating Molecular Biomarkers for the Diagnosis and Monitoring of NSCLC—A Review
Jelski, W., Okrasinska, S., Rutkowska, W., & Mroczko, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110278 · Cited by 5
Transforming ovarian cancer care by targeting minimal residual disease
Jazaeri, A. A., Grisham, R. N., Knisely, A. T., Spranger, S., Zamarin, D., Hillman, R. T., Lawson, B. C., Burns, K. H., Lee, S., Westin, S. N., et al. (2023) · Med · doi:10.1016/j.medj.2023.08.004 · Cited by 5
Liquid biopsy- A pivotal test to help navigate clinical decisions at a precision center in India!
Limaye, S. A., Shreenivas, A. V., Patil, D., Sambath, J., George, I. A., Parab, A., Datta, A., Jain, P., Singh, S., Madre, C., et al. (2025) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2025.100323 · Cited by 4
Development of Enzyme-Free DNA Amplifier Based on Chain Reaction Principle
He, S., Yang, Y., Xu, Z., Ling, H., Wang, Y., Li, W., Huang, N., Ye, Q., & Liu, Y. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.06.047 · Cited by 4
Runkel, A., Braig, D., Bogner, B., Schmid, A., Lausch, U., Boneberg, A., Brugger, Z., Eisenhardt, A., Kiefer, J., Pauli, T., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285580 · Cited by 4
Guardamagna, M., Zamorano, E., Albarrán-Artahona, V., Mesas, A., & Benítez, J. C. (2025) · Cancers · doi:10.3390/cancers17132244 · Cited by 5
Gu, R., Liu, T., Cheng, W., Li, M., Wang, X., & Jin, H. D. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70446 · Cited by 4
Ahmed, A., Saini, G., Ferguson, S. E., Fazelzad, R., Li, Q., Han, K., Pugh, T., Wong, D., Kim, R. H., Hodgson, A., et al. (2025) · Gynecologic Oncology · doi:10.1016/j.ygyno.2025.12.008 · Cited by 4
Stepan, L. P., Ansari, S., Abramson, J. S., Okal, A., Dell’Aringa, J., Thompson, E. G., Crotta, A., Chow, V. A., Kamdar, M. K., Solomon, S. R., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-03051 · Cited by 4
Self-citationBahabayi, A., Guan, Z., Zheng, M., Yu, H., Hasimu, A., Nie, Y., Zhao, M., Zhu, Y., Ren, J., Zhao, Y.-M., et al. (2024) · Immunology · doi:10.1111/imm.13819 · Cited by 4
Precision Medicine Approaches in Breast Cancer: Current Strategies and Future Directions
Idris, O. A., Deleon, N., Gustafson, M., Haj, D., & Zhang, T. (2024) · IntechOpen eBooks · doi:10.5772/intechopen.1007670 · Cited by 5
Circulating tumor DNA analysis: potential to revise adjuvant therapy for stage II colorectal cancer
Zhu, N., Hu, H., & Yuan, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01164-y · Cited by 4
Lin, C., Chen, Z., Kang, F., Hu, J., Huang, L., Liao, C., Lai, J., Huang, Y., Wang, Z., Tian, Y., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10992-2 · Cited by 4
McCall, S. J., Lubensky, I. A., Moskaluk, C. A., Parwani, A. V., Radin, K., Ramirez, N. C., von Menchhofen, Z., Washington, M. K., & LiVolsi, V. A. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0714 · Cited by 4
Cheng, A. P., Rusinek, I., Sossin, A., Widman, A. J., Meiri, E., Krieger, G., Hirschberg, O., Tov, D. S., Gilad, S., Jaimovich, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.11.669689 · Cited by 7
Circulating Tumor DNA as a Prognostic and Predictive Biomarker in Lung Cancer
Dhillon, P., Du, S., & Cheng, H. (2025) · Cancers · doi:10.3390/cancers17203327 · Cited by 4
Heo, S., Ham, S., Lee, H., Han, B., Roh, H., Jeong, S., Kim, H., Bang, D., Song, S., & Kim, T. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334282 · Cited by 3
Simulating cell-free chromatin using preclinical cancer models for liquid biopsy applications
Main, S. C., Michino, S. D. D., Penny, L., Aamir, A., Keshavarzian, T., Lok, B. H., Kridel, R., Cescon, D. W., Hoffman, M. M., Lupien, M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114113 · Cited by 3
Liu, L., Liang, W., Cao, W., Wang, H., Liang, H., Huang, L., Zhong, D., Gao, W. D., Deng, Q., Zhang, Y., et al. (2025) · MedComm · doi:10.1002/mco2.70483 · Cited by 4
Eskandar, K. (2025) · UroPrecision · doi:10.1002/uro2.70045 · Cited by 3
Zhang, J., Chen, K., Gao, X., Huang, C., Cui, Q., Kong, J., Zhang, Y., Jiao, Z., Yin, R., Li, Z., et al. (2026) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2026.103729 · Cited by 3
Liquid biopsies, are we ready for prime time?
Normanno, N., Apostolidis, K., & Stewart, M. D. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006302 · Cited by 3
Response of adrenocortical carcinoma liver metastases to hepatic artery infusion floxuridine
McDonald, H. G., Sarvestani, A. L., Owen, J. W., Rueckert, J., Wierman, M. E., Kiseljak‐Vassiliades, K., Pandalai, P. K., Ellis, C. S., Patel, R. A., Rivero, J. D., et al. (2023) · HPB · doi:10.1016/j.hpb.2023.06.014 · Cited by 3
Beecroft, J. R., Brar, S. S., Feng, X., Hamilton, T. D., Han-Lee, C., Henning, J., Josephy, P. D., Khalili, K., Ko, Y., Lemieux, C., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241266179 · Cited by 3
Breath- and blood-based molecular assessment for gastroesophageal cancer
Vanstraelen, S., Herpe, F. V., Dekervel, J., & Nafteux, P. R. (2025) · ESMO Gastrointestinal Oncology · doi:10.1016/j.esmogo.2025.100132 · Cited by 4
Who benefits from consolidation durvalumab in stage III non-small cell lung cancer?
Ruysscher, D. D., Remón, J., & Hendriks, L. E. L. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.02.015 · Cited by 3
Metadata
- Authors
- Moding, E. J., Nabet, B. Y., Alizadeh, A. A., & Diehn, M.
- Affiliations
- Stanford Medicine (US)
- Corresponding author
- Alizadeh, Ash A.
- Diehn, Maximilian
- Venue
- Cancer Discovery
- Published
- 2021-12-01
- Volume
- 11
- Issue
- 12
- Pages
- 2968-2986
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC8976700
- OpenAlex
- W3214322235
- Cited by
- 325
- References
- 114
- Citations by year
- 2026: 66 · 2025: 75 · 2024: 74 · 2023: 81 · 2022: 28 · 2021: 1
- FWCI
- 5.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- NIH (5R25CA180993)
- Postdoctoral Research Fellowship (134031-PF-19-164-01-TBG)
- Leukemia and Lymphoma Society NCI (R01CA257655, R01CA233975, R01CA188298)
- NCI (R01CA188298, R01CA233975, R01CA244526, R01CA254179)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Keywords
- circulating tumor DNA, minimal residual disease, solid tumors, recurrence prediction, liquid biopsy, adjuvant therapy, treatment response monitoring, liquid biopsy biomarkers, personalized treatment
- MeSH terms
- Circulating Tumor DNA, Humans, Neoplasm Recurrence, Local, Biomarkers, Tumor, Neoplasm, Residual
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
